SABS (SAB Biotherapeutics) ROCE %: -37.54% (As of Mar. 2026)


SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.84
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics ROCE %?

SAB Biotherapeutics SABS -1.03% 26 ROCE % is -37.54% as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SAB Biotherapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -37.54%.

SAB Biotherapeutics  (NAS:SABS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SAB Biotherapeutics ROCE % Related Terms

SAB Biotherapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics ROCE % Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -33.65 -40.65 -76.81 -61.80 13.63

SAB Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.41 -167.78 189.43 -40.14 -37.54
SABS
26GF Score
SAB Biotherapeutics Inc SABS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics ROCE % Calculation

SAB Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=13.514/( ( (44.195 - 7.98) + (172.81 - 10.681) )/ 2 )
=13.514/( (36.215+162.129)/ 2 )
=13.514/99.172
=13.63 %

SAB Biotherapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-75.224/( ( (172.81 - 10.681) + (248.47 - 9.852) )/ 2 )
=-75.224/( ( 162.129 + 238.618 )/ 2 )
=-75.224/200.3735
=-37.54 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -37.54% mean?
SAB Biotherapeutics (SABS) has a ROCE % of -37.54% as of Mar. 2026.
Is SAB Biotherapeutics' ROCE % too high?
SAB Biotherapeutics' current ROCE % is -37.54%. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' ROCE % compare to TRDA and ACIU?
SAB Biotherapeutics' ROCE % of -37.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. SAB Biotherapeutics's current ROCE % is -37.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current ROCE % of -37.54%. The current ROCE % is -37.54%. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current ROCE % is -37.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price